Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

Researchers leading the SWOG S1712 clinical trial have found that adding ... deep enough to warrant discontinuing treatment. A new preclinical model using CRISPR, an advanced technology that ...

Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the ...

Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of ...

Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The milestone achievement triggers a $10 million payment to Surrozen as part ...

"We are thrilled with the positive outcomes from our preclinical studies," Biolexis ... the biotech plans to conduct IND-enabling studies and begin human clinical trials early next year, chief ...

The neuraxial delivery of drugs has become a cornerstone in the management of pain, leveraging the pivotal roles of the dorsal root ganglion (DRG) and dorsal horn. These spinal structures are key in ...

Kineta will be trading under the symbol “KANT” on OTC PinkKineta will continue to pursue strategic alternatives as previously announcedTuHURA ...